Digitisation | November 14, 2023
Bayer and Recursion focus research collaboration on Oncology
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
European operations' revenue grew 58.4% to Rs 599.7 crore
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
PhytoSquene now available for clinical and commercial use
The agreement demonstrates a shared commitment to advance precision medicine and improve patient outcomes in the region
In 2022, darolutamide was FDA-approved in combination with docetaxel chemotherapy for adults with metastatic hormone-sensitive prostate cancer
Aster Whitefield will be Aster's 3 rd multi-specialty hospital in Bengaluru and overall 19th hospital in India
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
The companies plan to start a pivotal Phase 3 trial in the coming months
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
Subscribe To Our Newsletter & Stay Updated
